Teva earnings preview: Opioid suits are ‘key’


Teva Pharmaceutical Industries is scheduled to report third-quarter earnings on Thursday, and the struggling generic drugmaker’s recent opioid settlement is expected to take center stage.

J.P. Morgan analysts this week said that “opioids remain the key focus of the story” for Teva TEVA, +4.67%. In October, the Israeli drugmaker reached an opioid-related settlement with two Ohio counties.